Search Results
Your search for The ASCO Post matches 17812 pages
Showing 11551 - 11600Joanne Berger-Sweeney, PhD, MPH, Elected to Cold Spring Harbor Laboratory Board of Trustees
Cold Spring Harbor Laboratory has announced the election of Joanne Berger-Sweeney, PhD, MPH, President of Trinity College, to its Board of Trustees. “We are pleased to welcome Dr. Berger-Sweeney to the board of Cold Spring Harbor Laboratory. Her leadership at premier academic institutions in the...
Pembrolizumab Active in Mucosal Melanoma in KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO).1 Mucosal melanoma has often been excluded from...
Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach, in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA).1 Together, stomach and esophageal cancers...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
James Mohler, MD, Receives 2017 Rodger Winn Award
An accomplished urologic oncologist and longtime senior leader at Roswell Park Cancer Institute, James Mohler, MD, received the 2017 Rodger Winn Award at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference in Orlando, Florida. Dr. Mohler is Associate Director and Senior Vice...
Featured Lectures Presented at Society of Surgical Oncology
James Ewing Lecture: Jedd D. Wolchok, MD, PhD, presented the 2017 James Ewing Lecture on “Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms.” Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics...
FDA Permits Marketing for Digital Pathology Solution for Primary Diagnostic Use
The U.S. Food and Drug Administration (FDA) has permitted marketing of the Philips IntelliSite Pathology Solution (PIPS, Philips Medical Systems Nederland B.V.), as an aid to pathologists to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin...
FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was previously approved for people...
ASCO Releases Position Statement on Access to Investigational Drugs
ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal “right-to-try” legislation as well as state-enacted right-to-try laws. In a position statement released April 4, 2017, ASCO said ...
Deintensifiying Treatment of HPV-Positive Oropharyngeal Cancer Could Reduce Toxicity While Maintaining Function and Survival
“The status quo for HPV [human papillomavirus]-associated oropharyngeal squamous cell carcinoma is not sufficient.… Our treatment is effective, but the toxicity associated with it is not tolerable.” And HPV-associated oropharyngeal cancer “is a cancer of relatively younger patients,” said Nishant...
W.E. ‘Ed’ Bosarge, Jr, PhD, Honored With 2017 AACR Distinguished Public Service Award
The American Association for Cancer Research (AACR) presented an AACR Distinguished Public Service Award to W.E. “Ed” Bosarge, Jr, PhD, in honor of his generous, unstinting contributions to cancer research, innovative medical and environmental science, and the AACR. Dr. Bosarge is known for his...
Mark S. Soberman, MD, MBA, FACS, Named ACCC President
Mark S. Soberman, MD, MBA, FACS, was elected as the 2017–2018 President of the Association of Community Cancer Centers (ACCC) during its 43rd Annual Meeting on March 31, 2017, in Washington, DC. Dr. Soberman brings a wealth of experience in thoracic surgery, thoracic oncology, and value-based...
Medical Groups Unite in Support of March for Science
Twenty-five of the nation’s leading medical groups issued this statement on April 17: As the world's leading organizations representing clinicians, laboratory researchers, and physician-scientists committed to improving patient care, we support the March for Science and its nonpartisan call...
Attrition High but Positive Trends Observed in Web-Based Intervention Addressing Caregiver Burden
High attrition but positive trends such as increased “benefit finding” were observed with a Web-based intervention designed to address the psychosocial burden on informal caregivers, according to Allison J. Applebaum, PhD, a licensed clinical psychologist at Memorial Sloan Kettering Cancer Center...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice Guideline,” was published by Sher et ...
FDA Removes Risk Evaluation and Mitigation Strategy Requirements for Erythropoiesis-Stimulating Agents
On April 13, the U.S. Food and Drug Administration (FDA) removed the risk evaluation and mitigation strategy (REMS) requirements for the use of epoetin alfa and darbepoetin alfa to treat patients with anemia due to associated myelosuppressive chemotherapy. The Agency's announcement regarding...
Possible Link Between Androgen-Deprivation Therapy and Dementia
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen-deprivation therapy and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Previous studies from Penn have shown men who undergo...
U.S. Preventive Services Task Force Seeks Comments on Draft Recommendation Statement on Screening for Prostate Cancer
On April 11, the U.S. Preventive Services Task Force (USPSTF) posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with...
Ratio of T-Cell Invigoration to Tumor Burden Associated With Immunotherapeutic Response
Matching the size of a tumor to the body’s immune response could help physicians tailor immunotherapy treatments for patients with metastatic melanoma. Researchers found that patients who didn’t respond to treatment had an imbalance between the size of their tumor and how exhausted...
Preclinical Research Suggests Potential Therapy for 'Chemobrain'
Findings offered by a University of Kansas (KU) researcher at the national meeting of the American Chemical Society in early April suggest a possible therapeutic intervention for “chemobrain,” the cognitive impairment that plagues up to a third of cancer patients following chemotherapy. ...
New ACS CAN Report Examines Expected Patient Costs for Common Cancer Diagnoses
On April 11, the American Cancer Society Cancer Action Network (ACS CAN) released its first report examining the costs of treating cancer, specifically the out-of-pocket portion patients face. The report, released at the organization’s annual national policy forum, found U.S. cancer patients...
Potential Therapeutic Target for Malignant Teratoid/Rhabdoid Tumors Identified in Preclinical Study
Using state-of-the-art gene-editing technology, scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have discovered a promising target to treat atypical teratoid/rhabdoid tumor, a highly aggressive and therapy-resistant brain tumor that mostly occurs in infants. They found...
Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness
A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...
Study Finds Link Between Telomere Length and Neighborhood Circumstances
Researchers at Fox Chase Cancer Center have begun to establish a biological basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Annual Report to the Nation: Cancer Death Rates Continue to Decline
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the National Cancer Institute. The report...
FDA Grants Marketing Authorization for Ipsogen JAK2 RGQ PCR Kit to Detect JAK2 Genetic Mutations
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to the ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH, to detect mutations affecting the Janus tyrosine kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating...
AACR 2017: Telomere Length May Predict Cancer Risk, According to Large Epidemiologic Study
The length of the telomeres that protect the tips of chromosomes may predict cancer risk and be a potential target for future therapeutics, University of Pittsburgh Cancer Institute (UPCI) scientists reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting in...
AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Interim results from the phase Ib/II FB-10 clinical trial of neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1, Kadcyla) were reported in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, according...
Increased Recognition of Colorectal Cancer in Young Adults, Even Those Aged 20 to 29, as Evidence Continues to Accumulate
The incidence of colorectal cancer continues to increase among young adults, with the sharpest increase among those aged 20 to 29, according to a recent article in the Journal of the National Cancer Institute.1 This trend has been called disturbing and ominous, but the widely reported results of...
AACR Inducts 2017 Class of Fellows at Annual Meeting
The American Association for Cancer Research (AACR) inducted its newly elected class of Fellows of the AACR Academy at its Annual Meeting, held April 1–5, 2017, in Washington, DC. 2017 Class of Fellows Sir Adrian P. Bird, PhD, Buchanan Professor of Genetics, Wellcome Trust Centre for Cell Biology, ...
Forging a New Role to Make Curing More Cancers a Reality
For more than 3 decades, Nancy E. Davidson, MD, has dedicated her clinical and research career to better understanding the molecular mechanisms driving the development of breast cancer and to the discovery of more effective therapies to treat the disease. The recipient of an ASCO Young...
Practice-Changing Research: Making Palliative Care a Routine Part of Cancer Care in the United States and Abroad
With its recently issued clinical practice guideline update, reviewed in this issue of The ASCO Post, ASCO has spoken: Interdisciplinary palliative care teams improve the outcomes of cancer care; patients live longer and feel better.1 There is no doubt. Multiple well-designed studies show the...
Cardiac Dysfunction in Survivors of Adult Cancers
The success of cancer therapy has led us to an interesting place. Patients with cancer are certainly concerned about collateral damage that may occur with the treatment of their condition; however, impressive improvements in survival with treatment of many cancers are so compelling that these...
Fred Hutchinson’s Paulovich Laboratory to Lead Protein Assay Work for National Cancer Moonshot
The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, which represents a partnership among the National Cancer Institute (NCI), the Department of Defense, and the Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
Expert Point of View: Al Covens, MD
Al Covens, MD, Professor and Chair of Gynecologic Oncology at the University of Toronto, and Head of Gynecologic Oncology at Sunnybrook Health Science Centre, commented on the phase II findings of axalimogene filolisbac: “As almost all cervical cancers are human papillomavirus (HPV)-related, this...
Lauren Lawrence, MBA, RHIA, Appointed Vice President of Karmanos Cancer Network
Lauren Lawrence, MBA, RHIA, has been promoted to Vice President of Karmanos Cancer Network. She will report to Justin Klamerus, MD, MMM, President of Karmanos Cancer Hospital and Karmanos Cancer Network. Ms. Lawrence most recently served as Executive Director of Community-Based Programs at the...
Elizabeth M. Jaffee, MD, Named AACR President-Elect 2017–2018
Elizabeth M. Jaffee, MD, was elected by the members of the American Association for Cancer Research (AACR) as its President-Elect for 2017–2018. She officially became President-Elect at the AACR Annual Meeting 2017, held in Washington, April 1–5, and will assume the presidency in April 2018 at the ...
Deane L. Wolcott, MD, FAPOS, Receives Holland Distinguished Leadership Award
Deane L. Wolcott, MD, FAPOS, is the 2017 recipient of the Holland Distinguished Leadership Award, which was presented recently at the American Psychosocial Oncology Society (APOS) Annual Conference in Orlando, Florida. Dr. Wolcott is the founding Director of Oncology Supportive Care Services at...
JOP Publishes Clinical Pathways and Patient Safety Studies From Quality Care Symposium
The Journal of Oncology Practice (JOP) published three articles online in conjunction with the oral presentations of the data during ASCO’s 2017 Quality Care Symposium in Orlando. “The research presented at ASCO’s Quality Care Symposium enhances our understanding of a wide variety of methods to...
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (Bavencio) on March 23, 2017, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a...
AACR 2017: PRMT1 Identified as Potential Druggable Target for Pancreatic Cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma, according to results presented by Giuliani et al the 2017 Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC (Abstract 3016)....
AACR 2017: Minority Patients With Colorectal Cancer Report Higher Burden of Poor Quality-of-Life Than Whites
A study presented by Hildebrandt et al at the 2017 Annual Meeting of the American Association of Cancer Research (AACR; Abstract 990) revealed several findings about racial disparities in health-related quality of life among colorectal cancer patients. Hispanics and blacks had a higher burden of...
AACR 2017: Combination Immunotherapies Show Clinical Activity in Metastatic RCC in Pilot Study
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (RCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of...
AACR 2017: Ipilimumab/CVA21 Combination Treatment Shows Promise in Advanced Melanoma
Treatment with a combination of ipilimumab (Yervoy) and coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior treatment with an immune checkpoint inhibitor, and fewer-than-anticipated...
AACR 2017: Adding the IDO-Pathway Inhibitor Indoximod to Pembrolizumab Improved Response Rate in Melanoma
Adding the investigational immunotherapy indoximod to the immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously reported response rates for pembrolizumab monotherapy, according to interim results from a ...
AACR 2017: IDH-Mutant Cancers May Be More Amenable to Treatment With PARP Inhibitors Than IDH Inhibitors, According to Preclinical Findings
Tumors with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumors and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented by Sulkowski et al at the 2017 American...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer
Maintenance therapy with the tablet formulation of olaparib (Lynparza) significantly prolonged progression-free survival in patients with platinum-sensitive relapsed ovarian cancer and mutations in BRCA1/2 in the phase III SOLO2 trial, presented at the 2017 Society of Gynecologic Oncology (SGO)...
